康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CXO 康休

退市 07-17 07:47:28 EDT

65.60

+0.00

0.00%

最高65.60	最低65.60	成交量0.00
今开65.60	昨收65.60	日振幅0.00%
总市值127.60亿	流通市值126.27亿	总股本1.95亿
成交额0.00	换手率0.00%	流通股本1.92亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CXO","market":"US","secType":"STK","nameCN":"康休","latestPrice":65.6,"timestamp":1610744400000,"preClose":65.6,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":192489259,"shares":194506801,"eps":-52.266872,"marketStatus":"退市","change":0,"latestTime":"07-17 07:47:28 EDT","open":65.6,"high":65.6,"low":65.6,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-52.266872,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784295000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1186113600000,"exchange":"NYSE","adjPreClose":65.6,"dividendRate":0.011052,"volumeRatio":0},"requestUrl":"/m/hq/s/CXO","defaultTab":"news","newsList":[{"id":"2651451783","title":"昭衍新药净利最高增13.8倍：CXO破冰，先从一群实验猴开始","url":"https://stock-news.laohu8.com/highlight/detail?id=2651451783","media":"港股研究社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651451783?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:48","pubTimestamp":1784108880,"startTime":"0","endTime":"0","summary":"7月15日昭衍新药在港股高开超过12%，可见资本市场对CXO盈利修复的敏感度非同一般。2025年年度报告显示，昭衍新药当年实现收入16.58亿元，同比下降17.9%，其中非临床研究服务收入15.77亿元，占总收入95.1%；综合毛利率由25.0%降至20.71%，同比下降7.72个百分点。昭衍新药与常规CXO公司不同，其实验猴价格上涨可以同时影响资产价值、项目报价和实验成本，使利润表带有较强的商品周期特征。昭衍新药已经给出CXO行业离开底部的证据，尚未给出全面上行的终局答案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-15/doc-inihwrra4796564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06127","BK1576","CXO","603127","BK1141","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651272331","title":"港股异动 | CRO概念股今日普涨 内外需求共振行业向好 机构称CXO反弹具有业绩支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=2651272331","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651272331?lang=zh_cn&edition=full","pubTime":"2026-07-14 14:48","pubTimestamp":1784011706,"startTime":"0","endTime":"0","summary":"据报道称，当前食蟹猴身价已突破20万元。华鑫证券研报认为，从6月初至今，CXO板块在业绩和订单的支撑下，率先于创新药反弹。自6月8日至7月10日，CRO指数已反弹21.72%。展望下半年，创新药融资增长将继续支持CXO景气度延续。目前CRO龙头企业药明康德2027年预测PE为17.58X，凯莱英为33.19X。随着中期业绩临近，2季度订单趋势逐步明确，CXO反弹有望获得业绩支撑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348767384.USD","LU0708995583.HKD","BK4588","LU1046422090.SGD","LU0052750758.USD","06127","BK1583","BK1141","03759","LU2125910500.SGD","LU2242644610.SGD","LU0320764599.SGD","KCAI","VXUS","BK1576","06821","BK1191","LU2045819591.USD","CXO","LU0348766576.USD","02359","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651386126","title":"医药外包概念股普涨 凯莱英(06821)升逾4% 机构指CXO反弹有望获业绩支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=2651386126","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651386126?lang=zh_cn&edition=full","pubTime":"2026-07-14 10:51","pubTimestamp":1783997504,"startTime":"0","endTime":"0","summary":"2026年Q2Orforglipron等外企重磅品种获批上市，继续支撑药明康德订单增长。药明康德主动回购也彰显对未来信心，截止2026年6月25日，已回购金额超过10亿元。从6月初至今，CXO板块在业绩和订单的支撑下，率先于创新药反弹。自6月8日至7月10日，CRO指数已反弹21.72%。展望下半年，创新药融资增长将继续支持CXO景气度延续。目前CRO龙头企业药明康德2027年预测PE为17.58X，凯莱英为33.19X。随着中期业绩临近，2季度订单趋势逐步明确，CXO反弹有望获得业绩支撑。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985793","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348735423.USD","LU2242644610.SGD","LU0039217434.USD","LU0326950275.SGD","LU1794554557.SGD","LU1046422090.SGD","IE00B0JY6N72.USD","159938","LU0516423091.SGD","LU0456846285.SGD","BK1576","LU2045819591.USD","LU0348825331.USD","BK1515","LU1688375341.USD","KURE","LU0417516738.SGD","BK0239","LU0979878070.USD","BK0132","LU1242518857.USD","06821","LU0043850808.USD","LU2125910500.SGD","BK1574","LU0823426480.USD","BK1583","CXO","LU0516423174.USD","03759","002821","06127","LU0181495838.USD","LU0327786744.USD","LU0516422366.SGD","03347","BK1521","LU0051755006.USD","LU0856984785.SGD","LU0516422952.EUR","BK1161","02269","LU0456827905.SGD","BK1191","LU1720050803.USD","09939","02359","LU0708995583.HKD","LU3063872942.SGD","SG9999002463.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649995950","title":"大和：首予药明合联(02268)“买入”评级 列CXO首选","url":"https://stock-news.laohu8.com/highlight/detail?id=2649995950","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649995950?lang=zh_cn&edition=full","pubTime":"2026-07-08 11:40","pubTimestamp":1783482019,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大和发布研报称，首次给予药明合联“买入”评级，目标价78港元，并列为中国CXO行业首选股之一，指出药明合联是全球领先的抗体药物偶联物合约研究、开发及生产组织，亦是全球最大的纯ADC CRDMO企业，2025年市场份额达24%，预期受惠于快速增长的ADC外包市场及公司全链条CRDMO服务能力，该公司将能持续取得更多市场份额。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649920610","title":"生物科技板块全面走强 生物科技ETF易方达涨2.91%，康龙化成、泰格医药涨超5%领涨CXO赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2649920610","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649920610?lang=zh_cn&edition=full","pubTime":"2026-07-06 11:07","pubTimestamp":1783307249,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","GDOC","MEDX","BK4550","AGNG","BK4581","CXO","SYNB","FDN","XBI","BK4585","ARTY","XLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645815572","title":"药明康德今日大涨，一度“封板” 机构：创新药、CXO赛道迎估值修复行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2645815572","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645815572?lang=zh_cn&edition=full","pubTime":"2026-06-24 21:04","pubTimestamp":1782306277,"startTime":"0","endTime":"0","summary":"6月24日，A股、港股CXO（医药外包）及创新药板块迎来强势反弹行情，该板块个股集体冲高。其中，龙头股药明康德（SH603259）A股盘中强势涨停，一度“封板”，下午开盘后打开涨停板，报收115.40元/股，上涨8.55%。此外，凯莱英（SZ002821）也拉涨停“封板”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606243781645287.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606243781645287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1770034418.SGD","IE00B5MMRT66.SGD","LU2488822045.USD","LU2328871848.SGD","IE00B543WZ88.USD","LU1997244956.HKD","BK1161","LU2242644610.SGD","BK1583","LU0348767384.USD","LU0456842615.SGD","CXO","LU1969619763.USD","BK1576","LU0320764599.SGD","06978","BK1141","LU0708995583.HKD","LU0348766576.USD","LU1303224171.USD","IE00BPRC5H50.USD","159992","LU1934453819.USD","LU2495084118.USD","LU1251922891.USD","LU1979443071.USD","LU1719994722.HKD","02359","LU1997245177.USD","LU2045819591.USD","603259","LU0052750758.USD","LU2125910500.SGD","LU1997245094.SGD","LU1046422090.SGD","LU1808992512.USD","BK0216","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645897118","title":"CXO成反弹急先锋？高CXO含量港股通医疗ETF华宝（159137）盘中劲涨5.44%！创新药同步回血，520880上探4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645897118","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645897118?lang=zh_cn&edition=full","pubTime":"2026-06-24 19:26","pubTimestamp":1782300360,"startTime":"0","endTime":"0","summary":"6月24日，港股通医药久违大涨，创新药产业链强劲反攻！CXO一马当先：凯莱英狂飙13.12%，金斯瑞生物科技涨11.5%紧随其后，药明系权重龙头药明合联、药明康德、药明生物分别收涨8.88%、8.33%、4.17%。　　港股通医疗ETF华宝超四成仓位布局CXO龙头，盘中最高涨幅达5.44%尽显高弹性，收涨4.35%连收5日及10日均线，成交6531万元创近4个月新高！　　中报季临近，多家机构重点提示CXO板块投资机会，其中华福证券明确表示，重视CXO全年战略配置价值，并给出三点依据：","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-06-24/doc-iniepeiq1495055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","159992","CXO","BK1574","06978","159137","BK1161","VXUS","BK4588","520880","512170"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645866019","title":"CXO概念走强 凯莱英 (06821) 涨 17.77% BIO2026大会看好中国CXO高效率优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2645866019","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645866019?lang=zh_cn&edition=full","pubTime":"2026-06-24 11:17","pubTimestamp":1782271026,"startTime":"0","endTime":"0","summary":"全球生物技术领域盛会BIO2026大会于6月22日至25日在美国圣地亚哥召开，汇聚全球超20000名行业参与者，覆盖人工智能与数字健康、细胞与基因治疗等前沿领域，中国CXO企业的高效率优势备受关注。光大证券研报指，2026年6月22日至25日BIO2026大会举办，70余个国家超2万名业内人士参会，覆盖18大生物医药核心议题，凯莱英、泰格医药、博腾股份等国内CXO企业参展，英硅智能同期落地AI药物研发海外合作。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984377","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","LU2242644610.SGD","LU0456827905.SGD","BK1141","LU1794554557.SGD","LU0052750758.USD","BK0239","LU1046422090.SGD","LU0140636845.USD","LU0043850808.USD","LU1720050803.USD","LU0516422366.SGD","BK1521","LU0320764599.SGD","LU1328615791.USD","LU0327786744.USD","LU2039709279.SGD","LU0588546209.SGD","03759","BK0132","HK0000306685.HKD","03347","LU0051755006.USD","02269","06821","01548","HK0000306701.USD","LU0516422952.EUR","LU0572944931.SGD","LU0348735423.USD","LU0456846285.SGD","CXO","BK1583","LU1242518931.SGD","LU0856984785.SGD","LU0326950275.SGD","SG9999002463.SGD","LU1880383366.USD","LU0359201612.USD","002821","LU0708995583.HKD","HK0000320223.HKD","02359","LU0819121731.USD","HK0000320264.USD","LU3063872942.SGD","LU0359202008.SGD","06127","LU0348766576.USD","LU0039217434.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645653708","title":"港股异动 | CRO概念股表现强势 BIO大会凸显中国CXO全球竞争力 医药领域开放迎来新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2645653708","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645653708?lang=zh_cn&edition=full","pubTime":"2026-06-24 10:00","pubTimestamp":1782266401,"startTime":"0","endTime":"0","summary":"消息面上，BIO 2026国际生物科技大会于6月22日至25日在美国圣地亚哥召开，中国CXO企业的高效率优势得到全球认可，海外订单拓展空间进一步打开。东方证券发布研报称，从CXO景气度关键指标的最新数据来看：2026年前五个月，国内资金端、研发端、订单端多重因素共振向上，国内CXO行业高景气持续。该行认为，国内CXO公司订单充足、量价双升，随着订单执行转化，将会带来报表端大幅改善。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1046422090.SGD","LU0348767384.USD","02359","BK1191","BK4121","HK0000306701.USD","LU2045819591.USD","CXO","03347","BK4588","BK1574","LU0320764599.SGD","VXUS","LU2125910500.SGD","09939","BK1161","HK0000320223.HKD","HK0000306685.HKD","BIO","LU1169590202.USD","06821","LU0052750758.USD","LU0708995583.HKD","BK1141","BK1515","BK4585","01548","HK0000320264.USD","BK1576","LU2242644610.SGD","BK1583","159938","LU1169589451.USD","LU0348766576.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640468995","title":"方正证券：坚守创新药和CXO 关注跨界公司的超额成长性","url":"https://stock-news.laohu8.com/highlight/detail?id=2640468995","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640468995?lang=zh_cn&edition=full","pubTime":"2026-06-02 09:16","pubTimestamp":1780363008,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，方正证券发布研报称，今年以来医药板块表现相对平淡，去年创新药BD情绪带动子板块超额修复，今年陆续进入兑现期，部分兑现度较差的公司拖累了指数表现，但该行仍然认为创新药出海是目前医药板块中最重要的成长方向，仍然需要坚守创新药及CXO板块，此外受科技整体周期的情绪拉动，部分医药跨界AI基建的公司也有超额表现，适当关注拥有跨界业务的耗材板块。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","BK0028","BK0012","BK0188","BK0122","06978","159992","BK0276","BK1161","BK0183","BK1574","601901"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635406847","title":"A股药企突遭国际巨头4.3亿元索赔，20 厘米跌停，撕开 CXO 出海隐痛","url":"https://stock-news.laohu8.com/highlight/detail?id=2635406847","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635406847?lang=zh_cn&edition=full","pubTime":"2026-05-16 17:51","pubTimestamp":1778925084,"startTime":"0","endTime":"0","summary":"A股药企博腾股份突发重大海外纠纷，旗下欧洲基地被国际巨头单方面解约，且被索要4.3亿元巨额赔偿。利空消息一出，该股开盘直接20厘米跌停，在资本市场引发剧烈震动。这家曾靠新冠订单一战成名的小分子CDMO龙头，四年间走完一轮完整的业绩大起大落：从年净利润超20亿元的高光巅峰，一路回落陷入亏损泥潭，2025年刚实现扭亏企稳，又深陷海外合约风波、巨额索赔与股价重挫的多重压力之中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605163739616550.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605163739616550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159982","399300","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635076637","title":"国金证券：CXO内外需共振向上 新分子赋能行业持续扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2635076637","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635076637?lang=zh_cn&edition=full","pubTime":"2026-05-14 10:35","pubTimestamp":1778726116,"startTime":"0","endTime":"0","summary":"CXO行业进入内外需共振、新分子赛道放量、订单与业绩逐季改善的新一轮复苏上行周期。从海外CXO龙头企业的经营业绩与业绩指引调整趋势来看，2025年多家海外CXO公司逐季度上调全年业绩预期，盈利修复节奏持续超市场预期。展望2026年，海外头部CXO企业收入指引仍维持稳健小幅增长格局，叠加全球生物医药投融资逐步回暖、创新药研发需求稳步复苏，行业景气度延续上行态势，成长确定性进一步增强。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","BK0012","BK0028","BK0201","BK0276","BK0183","BK0188","600109"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635931274","title":"【券商聚焦】招银国际：宏观不确定性下 维持海外主要CXO和生命科学上游公司26年业绩指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2635931274","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635931274?lang=zh_cn&edition=full","pubTime":"2026-05-13 13:33","pubTimestamp":1778650438,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际总结了海外主要CXO和生命科学上游公司的1Q26业绩。1Q26主要海外CXO及上游公司业绩延续2025年逐季改善趋势，CMO仍是增速最快板块。多数公司新签订单同比增长，几乎所有企业维持2026年业绩指引不变。Medpace在1Q26项目取消数达一年高点，反映biotech临床需求脆弱，行业仍将面临需求波动。1Q26全球十大药企合计研发支出增43.5%，资本开支同比增8.0%；十大头部biotech研发支出同比降4.6%，资本开支同比降14.5%，其对CXO依赖度有望提升。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981262","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633687104","title":"【券商聚焦】中国银河：医药行业进入复苏周期 CXO板块景气度较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2633687104","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633687104?lang=zh_cn&edition=full","pubTime":"2026-05-08 09:00","pubTimestamp":1778202049,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国银河证券表示，2025年医药行业上市公司营业收入增长0.4%，归母净利润增长3.9%，扣非净利润下降4.1%，2026年一季度营业收入增长1.1%，归母净利润下降3.2%，扣非净利润增长2.0%。2025全年医药行业收入端小幅微增，主要系医保控费趋严，仿制药、耗材等集采常态化开展导致行业承压。2026年一季度创新药产业链高景气度延续，收入增幅扩大、非经常性损益占比下降，行业整体经营盈利能力提升，进入复苏上行周期。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980878","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1719994722.HKD","LU0634319403.HKD","BK1197","LU0348766576.USD","LU0348783233.USD","LU1251922891.USD","LU0417516902.SGD","LU2488822045.USD","LU0417516571.SGD","01789","02268","BK0188","BK0276","BK1207","LU1794554557.SGD","LU0561508036.HKD","LU0417516738.SGD","LU0640798160.USD","01099","BK1583","LU0588546209.SGD","LU2476274720.SGD","01530","BK1593","LU1969619763.USD","06881","06160","BK1161","LU1303224171.USD","LU0348767384.USD","BK1588","CXO","03933","601881","02196","LU2328871848.SGD","LU0348735423.USD","LU2778985437.USD","BK1500","02228","02367","09926","BK1585","IE00BPRC5H50.USD","LU0307460666.USD","BK1141","HK0000165453.HKD","LU1961090484.USD","09688","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630045413","title":"智通港股解盘 | 各种负面冲击恒指出现调整 4月金股药明康德(02359)引领CXO","url":"https://stock-news.laohu8.com/highlight/detail?id=2630045413","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630045413?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:21","pubTimestamp":1777378875,"startTime":"0","endTime":"0","summary":"拟套现约 4.9 亿，此前累计套现 13.4 亿，今天跌超 12%。一解禁抛盘汹涌，下跌超 16%。截至 2026 年 3 月末，持续经营业务在手订单 597.7亿元，同比增长 23.6%，为全年业绩提供较强可见度。希腊船舶经纪公司 Exclusive27 日表示，由于霍尔木兹海峡通航受限，部分油轮被滞留，可用运力减少。航线不确定性加剧推动油轮短期租赁运费飙升。此外，公司宣布派发末期股息每股 35 港仙。出口量稳居高位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435488.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK0216","LU2045819591.USD","00631","02039","BK1505","BK4588","LU1979443071.USD","LU0348766576.USD","BK1171","LU2488822045.USD","LU2242644610.SGD","603259","BK1507","HSI","BK1183","LU1997245094.SGD","513600","LU2495084118.USD","BK1583","02833","LU0708995583.HKD","LU1997245177.USD","HHImain","LU0320764599.SGD","LU1046422090.SGD","LU1969619763.USD","LU0052750758.USD","02359","HSImain","LU0348767384.USD","CXO","BK1548","MCHmain","LU2328871848.SGD","LU0456842615.SGD","BK1576","LU1808992512.USD","LU1934453819.USD","00317","MHImain","BK1141","LU1997244956.HKD","LU2125910500.SGD","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630132145","title":"别只盯着AI！CXO龙头绩后狂飙，医药赛道要接棒？","url":"https://stock-news.laohu8.com/highlight/detail?id=2630132145","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630132145?lang=zh_cn&edition=full","pubTime":"2026-04-28 12:12","pubTimestamp":1777349565,"startTime":"0","endTime":"0","summary":"新一轮行情蓄势待发？","market":"fut","thumbnail":"https://img3.gelonghui.com/24523-2e652654-d4de-433f-93f9-afc3a2669c93.jpg?guru_height=718&guru_width=1280&guru_size=85166","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/24523-2e652654-d4de-433f-93f9-afc3a2669c93.jpg?guru_height=718&guru_width=1280&guru_size=85166"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4574522","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU0320764599.SGD","002821","BK1574","BK0239","159938","LU0348766576.USD","09939","CHAT","BK1515","BK1161","AGIX","06821","BK1576","LU0708995583.HKD","LU1046422090.SGD","BK0132","BK1583","BK1141","603127","AIPO","LU2242644610.SGD","BK1191","06127","BK0216","LU1328615791.USD","CXO","LU0052750758.USD","ARTY","LU2125910500.SGD","02359","LU0348767384.USD","LU2045819591.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630340844","title":"“CXO一哥”一季度营收首破“百亿”，A、H股CXO概念走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2630340844","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630340844?lang=zh_cn&edition=full","pubTime":"2026-04-28 10:01","pubTimestamp":1777341660,"startTime":"0","endTime":"0","summary":"早盘，A股CXO概念走强，凯莱英、药明康德涨停，博腾股份、康龙化成、毕得医药、诚达药业等跟涨。港股方面，药明康德涨超16%，药明生物、康龙化成、泰格医药等跟涨。消息面上，4月27日，“CXO一哥”药明康德公告称，2026年第一季度实现营业收入124.36亿元，同比增长28.81%，首次在第一季度迈入百亿大关；归属于上市公司股东的净利润为46.52亿元，同比增长26.68%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283721714535.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283721714535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630786369","title":"三个月股价几近“腰斩”，维亚生物(01873)为何没跟上CXO企稳反弹脚步？","url":"https://stock-news.laohu8.com/highlight/detail?id=2630786369","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630786369?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:08","pubTimestamp":1777280903,"startTime":"0","endTime":"0","summary":"在今年1月底股价反弹至阶段性高点2.86港元之后，维亚生物的股价便开始了一段近3个月的下跌行情。3月30日，维亚生物正式披露公司2025年年度业绩。没跟上CXO企稳反弹脚步?近期，AH两地CXO企业已陆续披露2025年年报。以维亚生物为例，近三个月来，维亚生物股价持续回调。可以看到，维亚生物股价3月17日之后进一步阴跌，并且后续股价一直在BOLL线中下轨震荡，市场情绪低迷。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1576","CXO","01873"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628395711","title":"中国银河证券：CXO助力小核酸加速发展 国产管线蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2628395711","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628395711?lang=zh_cn&edition=full","pubTime":"2026-04-20 13:44","pubTimestamp":1776663860,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，小核酸产业链国内处于起步阶段，国产替代空间大，CXO助力行业加速发展。中游CDMO企业提供小核酸药物外包研发服务，助力国内小核酸药物行业的快速发展。中国银河证券主要观点如下：从小核酸药物英克司兰跻身重磅药物行列，看小核酸药物高成长属性诺华2025年度财报：全球首款siRNA超长效降脂药Leqvio全年销售额飙至11.98亿美元，同比增长57%，跻身重磅药物行列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1147","601881","BK0276","161027","CXO","BK1564","06881","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628221164","title":"港股异动 | CXO 概念股跌幅居前 海外投融资大环境进入波动阶段 AI制药或导致研发及临床端分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2628221164","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628221164?lang=zh_cn&edition=full","pubTime":"2026-04-17 11:31","pubTimestamp":1776396664,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CXO概念股跌幅居前，截至发稿，昭衍新药跌5.82%，报21.7港元；康龙化成跌3.65%，报21.1港元；泰格医药跌3.02%，报42.46港元。中信建投发布研报称，海外投融资大环境进入季度间波动，不同阶段、不同疾病领域的CXO服务需求进一步分化，国内投融资活动景气度持续上行，弹性更强，持续看好CXO板块成长空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1574","AGIX","BK1141","BK1583","ARTY","03759","01477","AIPO","BK4585","BK1191","VXUS","06127","CHAT","CXO","03347","BK1576"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.concho.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0013},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0571},{"period":"6month","weight":0.0854},{"period":"1year","weight":0.2027},{"period":"ytd","weight":0.1009}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Concho Resources Inc.成立于2006年2月22日，是一家于2006年2月在特拉华州注册成立的公司，是一家独立的石油和天然气公司，从事石油和天然气资产的收购、开发、勘探和生产。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.054246},{"month":2,"riseRate":0.384615,"avgChangeRate":-0.002949},{"month":3,"riseRate":0.692308,"avgChangeRate":0.024071},{"month":4,"riseRate":0.769231,"avgChangeRate":0.069872},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.030229},{"month":6,"riseRate":0.461538,"avgChangeRate":0.004495},{"month":7,"riseRate":0.692308,"avgChangeRate":0.012949},{"month":8,"riseRate":0.461538,"avgChangeRate":-0.02419},{"month":9,"riseRate":0.571429,"avgChangeRate":0.015298},{"month":10,"riseRate":0.5,"avgChangeRate":0.017047},{"month":11,"riseRate":0.571429,"avgChangeRate":0.047858},{"month":12,"riseRate":0.642857,"avgChangeRate":0.007299}],"exchange":"NYSE","name":"康休","nameEN":"Concho Resources"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康休,CXO,康休股票,康休股票老虎,康休股票老虎国际,康休行情,康休股票行情,康休股价,康休股市,康休股票价格,康休股票交易,康休股票购买,康休股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康休(CXO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康休(CXO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}